Advances in Veterinary Pharmacology: Improving Treatment Modalities for Animal Pathology

A special issue of Animals (ISSN 2076-2615). This special issue belongs to the section "Veterinary Clinical Studies".

Deadline for manuscript submissions: 15 June 2025 | Viewed by 1161

Special Issue Editors


E-Mail Website
Guest Editor
Institute of Biology, Pomeranian Uniwersity in Słupsk, Słupsk, Poland
Interests: oxidative stress; antioxidant defence; biochemical changes; mitochondrial respiration; hemolysis; melatonin; L-arginine; Krebs cycle intermediates
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Institute of Biology, Pomeranian Uniwersity in Słupsk, Słupsk, Poland
Interests: pollution-induced oxidative damage; toxicity and oxidative injury; heavy metals; ecotoxicology; ecophysiology; nitric oxide; environmental stressors; environmental stressors in human and animal health; antioxidant defense in pathology; redox imbalance in human and animal diseases
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Over the past decade, the importance of advancing veterinary pharmacology to meet evolving challenges in animal health has become paramount. The complex interplay between genetics, environmental factors, and physiological variation requires a nuanced approach to drug development and administration in veterinary medicine. As our responsibility for animal welfare grows, so too must our commitment to refining and expanding the pharmacological tools at our disposal. The development of novel drugs, the optimization of dosing regimens, and the exploration of targeted therapies are critical elements for safeguarding the health and welfare of animals worldwide. In addition, veterinary pharmacology contributes to the concept of One Health, which recognizes the interconnectedness of animal, human, and environmental health. By improving our understanding of how medicines interact with different species, we not only improve the care of animals, but also contribute to wider public health initiatives and the ecological balance.

This Special Issue aims to provide a comprehensive platform for the dissemination of cutting-edge research that advances the field of veterinary pharmacology, and will be focused on recent research or reviews that explore novel approaches, breakthroughs, and advances that contribute to the development of improved treatment modalities for various animal pathologies.

In this Special Issue, original research articles and reviews are welcome, and research areas may include, but are not limited to, the following:

  • Research of novel compounds and therapeutic agents tailored to specific animal pathologies;
  • Studies of the absorption, distribution, metabolism, and excretion of veterinary drugs and their dynamic interactions in different species;
  • Investigation of the pharmacological requirements and responses of different species to optimize treatment outcomes;
  • Research to refine dosing regimens to improve the efficacy and safety of veterinary medicines and to minimize adverse effects;
  • Advances in the development and application of targeted therapies, taking into account individual differences in animals;
  • The interconnectedness of animal, human, and environmental health, in line with the One Health framework.

We look forward to receiving your contributions.

Dr. Halina Tkaczenko
Prof. Dr. Natalia Kurhaluk
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Animals is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • veterinary pharmacology
  • animal pathology
  • drug discovery
  • pharmacokinetics
  • pharmacodynamics
  • dosage optimization
  • targeted therapies
  • personalized medicine for animals

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

10 pages, 1267 KiB  
Article
Effect of Body Size on Plasma and Tissue Pharmacokinetics of Danofloxacin in Rainbow Trout (Oncorhynchus mykiss)
by Kamil Uney, Duygu Durna Corum, Pedro Marín, Devran Coskun, Ertugrul Terzi, Elena Badillo and Orhan Corum
Animals 2024, 14(22), 3302; https://doi.org/10.3390/ani14223302 - 16 Nov 2024
Viewed by 678
Abstract
Danofloxacin is a fluoroquinolone antibiotic approved for use in fish. It can be used for bacterial infections in fish of all body sizes. However, physiological differences in fish depending on size may change the pharmacokinetics of danofloxacin and therefore its therapeutic efficacy. In [...] Read more.
Danofloxacin is a fluoroquinolone antibiotic approved for use in fish. It can be used for bacterial infections in fish of all body sizes. However, physiological differences in fish depending on size may change the pharmacokinetics of danofloxacin and therefore its therapeutic efficacy. In this study, the change in the pharmacokinetics of danofloxacin in rainbow trout of various body sizes was revealed for the first time. The objective of this investigation was to compare the plasma and tissue pharmacokinetics of danofloxacin in rainbow trout of different body sizes. The study was conducted at 14 ± 0.5 °C in fish of small, medium, and large body size and danofloxacin was administered orally at a dose of 10 mg/kg. Concentrations of this antimicrobial in tissues and plasma were quantified by high performance liquid chromatography with ultraviolet detector. The plasma elimination half-life (t1/2ʎz), volume of distribution (Vdarea/F), total clearance (CL/F), peak concentration (Cmax), and area under the plasma concentration–time curve (AUC0–last) were 27.42 h, 4.65 L/kg, 0.12 L/h/kg, 2.53 µg/mL, and 82.46 h·µg/mL, respectively. Plasma t1/2ʎz, AUC0–last and Cmax increased concomitantly with trout growth, whereas CL/F and Vdarea/F decreased. Concentrations in liver, kidney, and muscle tissues were higher than in plasma. Cmax and AUC0–last were significantly higher in large sizes compared to small and medium sizes in all tissues. The scaling factor in small, medium, and large fish was 1.0 for bacteria with MIC thresholds of 0.57, 0.79, and 1.01 µg/mL, respectively. These results show that therapeutic efficacy increases with body size. However, since increases in danofloxacin concentration in tissues of large fish may affect withdrawal time, attention should be paid to the risk of tissue residue. Full article
Show Figures

Graphical abstract

Back to TopTop